title: [A case of sigmoid colon cancer with peritoneal dissemination responding to third-line therapy employing bevacizumab combination therapy after failure of FOLFOX and FOLFIRI].
abstract: A58 -year-old man with sigmoid colon cancer with peritoneal dissemination was treated with bevacizumab (BV) plus mFOLFOX6 therapy as third-line chemotherapy after treatment failures with FOLFOX4 and FOLFIRI regimen. BV combination therapy resulted in a decrease in ascites and disappearance of the primary lesion. His ECOG performance status (PS) recovered from level 3 to level 1, and BV combination therapy improved his quality of life. This case suggested that BV in combination with chemotherapy could be a promising systemic chemotherapy for patients with colorectal cancer with peritoneal dissemination, and this regimen may be useful for patients progressing after receiving FOLFOX, FOLFIRI regimen.
authors.affiliation: Dept. of Surgery, Kyushu Rosai Hospital, Japan.
authors.forename: Toshihisa
authors.initials: T
authors.lastname: Tamura
authors.forename: Nami
authors.initials: N
authors.lastname: Ishikawa
authors.forename: Shirou
authors.initials: S
authors.lastname: Koui
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nakashima
authors.forename: Noritaka
authors.initials: N
authors.lastname: Minagawa
authors.forename: Yasutaka
authors.initials: Y
authors.lastname: Hachiya
authors.forename: Keiji
authors.initials: K
authors.lastname: Hirata
authors.forename: Tatsuhiko
authors.initials: T
authors.lastname: Sako
authors.forename: Tokihiko
authors.initials: T
authors.lastname: Fukuyama
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Hirano
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D010534:Peritoneal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary; D012811:Sigmoid Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D014057:Tomography, X-Ray Computed; D017211:Treatment Failure
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin